Sustained drug-releasing stent

A stent comprising:

• a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces;
• a first coated layer coating at least the outer surface of the stent body and having a thickness within the range of 1 to 15 μm, the first coated layer being prepared of a first composition comprising a biodegradable polymer and argatroban, the weight compositional ratio of the polymer to the argatroban being within the range of 8:2 to 3:7, the argatroban being micro-dispersed in crystal state in the first composition;
• and
• a second coated layer coating substantially completely over the first coated layer and having a thickness within the range of 0.5 to 5 μm, the second coated layer being prepared of a biodegradable polymer alone or a second composition comprising a biodegradable polymer and a drug, the weight compositional ratio of the drug being less than 20% by weight of the second composition.

A stent comprising:

• a stent body of a cylindrical configuration having outer and inner surfaces without a diamond-like thin film coated on the surfaces;
• a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the inhibitor being micro-dispersed in crystal state in the first composition;
• and
• a second coated layer coating substantially completely over the first coated layer, the second coated layer being prepared of a biodegradable polymer alone or a second composition comprising a biodegradable polymer and a drug, the weight compositional ratio of the drug being less than 20% by weight of the second composition.

A stent comprising:

• a stent body of a cylindrical configuration having outer and inner surfaces without a diamond-like thin film coated on the surfaces;
• a first coated layer coating at least the outer surface of the stent body and having a thickness within the range of 1 to 15 μm, the first coated layer being prepared of a first composition comprising a biodegradable polymer and argatroban, the weight compositional ratio of the polymer to the argatroban being within the range of 8:2 to 3:7, the argatroban being micro-dispersed in crystal state in the first composition;
• and
• a second coated layer coating substantially completely over the first coated layer and having a thickness within the range of 0.5 to 5 μm, the second coated layer being prepared of a biodegradable polymer alone or a second composition comprising a biodegradable polymer and a drug, the weight compositional ratio of the drug being less than 20% by weight of the second composition.